Results 131 to 140 of about 2,581 (157)

Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males

Journal of Cystic Fibrosis, 2021
I Bronsveld, H G M Arets, H G M Heijerman   +2 more
exaly  

Ivacaftor/ivacaftor/lumacaftor

Reactions Weekly, 2022
openaire   +1 more source

Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis

Biomolecules, 2021
Silvia Franceschelli, Franceschelli Silvia   +1 more
exaly  

Ivacaftor/lumacaftor

Reactions Weekly
openaire   +2 more sources

Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR

American Journal of Respiratory and Critical Care Medicine, 2017
CARLOS Milla, Margaret Rosenfeld, Felix Ratjen   +2 more
exaly  

Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa

American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018
Bruce A Stanton, Thomas H Hampton, Katja Koeppen   +2 more
exaly  

Lumacaftor (VX-809)

Drugs of the Future, 2012
null McPhail, G., null Clancy, J.P.
openaire   +1 more source

Crystalline form of lumacaftor

2019
SOUZA FABIO E S, KHALILI BAHAREH, RANTANEN KATHERINE A   +2 more
openaire   +2 more sources

Brivaracetam, lumacaftor/ivacaftor, and deoxycholic acid

Journal of the American Pharmacists Association, 2016
Daniel A, Hussar, Jerry Rachel, George
openaire   +2 more sources

Ivacaftor/lumacaftor/ivacaftor/tezacaftor

Reactions Weekly, 2023
openaire   +1 more source